Natco Pharma

{
  "main_header": {
    "sid": 156274,
    "name": "Natco Pharma",
    "stock_name": "Natco Pharma",
    "full_name": "Natco Pharma Ltd.",
    "name_url": "stocks-analysis/natco-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "888.75",
    "chg": 5.5,
    "chgp": "0.62%",
    "dir": 1,
    "prev_price": "883.25",
    "mcapval": "15,939.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524816,
    "symbol": "NATCOPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE987B01026",
    "curr_date": "Jun 19, 03:30 PM",
    "curr_time": "07:41 AM",
    "last_traded_at": "Jun 19, 03:30 PM IST",
    "bse_nse_vol": "10.58 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 19, 2026",
    "traded_date_str": "2026 06 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/natco-pharma-156274-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Natco Pharma Ltd. is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/natco-pharma-ltd-is-rated-hold-4063024",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NatcoPharmaLtd_mojoScore_4063024.png",
        "date": "2026-06-19 10:11:29",
        "description": "Natco Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Natco Pharma Falls 12.11%: Key Technical Shifts and Market Pressures This Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-falls-1211-key-technical-shifts-and-market-pressures-this-week-4053183",
        "imagepath": "",
        "date": "2026-06-14 16:02:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Intraday low hit amid heavy price pressure</p>\n                    <p><strong>1 June:</strong> Technical momentum shifts observed amid volatile conditions</p>\n                    <p><strong>5 June:</strong> Week closes at Rs.893.65, down 12.11%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,016.75</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.893.65</div><div class=\"stat-change negative\">-12.11%</div></div>\n                    <div class=\"stat-item\"><div class..."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/natco-pharma-ltd-is-rated-hold-by-marketsmojo-4037127",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NatcoPharmaLtd_mojoScore_4037127.png",
        "date": "2026-06-08 10:10:40",
        "description": "Natco Pharma Ltd. is currently rated 'Hold' by MarketsMOJO, with this rating last updated on 10 March 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Natco Pharma Ltd. Hits Intraday Low Amid Price Pressure on 1 June 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-hits-intraday-low-amid-price-pressure-on-1-june-2026-4026146",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NatcoPharmaLtd_priceRelatedfactors_4026146.png",
        "date": "2026-06-01 10:16:51",
        "description": "Natco Pharma Ltd. experienced significant intraday weakness on 1 Jun 2026, with its share price touching a low of Rs 942.45, down 7.31% from the previous close. The stock underperformed its sector and the broader market, reflecting immediate selling pressure amid a cautious market environment."
      },
      {
        "title": "Natco Pharma Ltd. Technical Momentum Shifts Amid Volatile Market Conditions",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-technical-momentum-shifts-amid-volatile-market-conditions-4024930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NatcoPharmaLtd_technicaldot_4024930.png",
        "date": "2026-06-01 08:00:24",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals. Despite a sharp day decline of 13.51%, the stock’s year-to-date and longer-term returns continue to outperform the Sensex, signalling underlying resilience amid recent volatility."
      },
      {
        "title": "Are Natco Pharma Ltd. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-natco-pharma-ltd-latest-results-good-or-bad-4023803",
        "imagepath": "",
        "date": "2026-05-30 19:44:38",
        "description": "Natco Pharma Ltd.'s latest financial results for Q4 FY26 reveal a complex picture of operational performance. The company reported a net profit of ₹267.90 crores, which reflects a significant quarter-on-quarter growth of 76.83%. However, this figure is accompanied by a year-on-year decline of 34.11%, indicating challenges in sustaining profitability over a longer period. \n\nNet sales for the quarter reached ₹739.10 crores, marking a 14.18% increase from the previous quarter, yet this is overshadowed by a substantial year-on-year decrease of 39.47%. This suggests that while there may be some recovery from the previous quarter, the overall trend remains concerning, particularly given the sharp decline in sales compared to the same quarter last year.\n\nThe operating margin, excluding other income, fell to 17.26%, which is noted as a multi-quarter low. This decline in operating margin indicates significant pressu..."
      },
      {
        "title": "Natco Pharma Q4 FY26: Sharp Revenue Decline Overshadows Tax Reversal Gains",
        "link": "https://www.marketsmojo.com/news/result-analysis/natco-pharma-q4-fy26-sharp-revenue-decline-overshadows-tax-reversal-gains-4023587",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NatcoPharma_quaterlyResult_4023587.png",
        "date": "2026-05-30 12:16:10",
        "description": "Natco Pharma Ltd. reported consolidated net profit of ₹267.90 crores for the quarter ended March 2026, marking a sharp 76.83% quarter-on-quarter surge but a concerning 34.11% year-on-year decline. The Hyderabad-based pharmaceutical manufacturer, with a market capitalisation of ₹21,264 crores, witnessed its stock plummet 13.51% following the results announcement, closing at ₹1,016.75 on May 29, 2026. The quarter's performance reveals a troubling divergence: whilst net profit appeared robust due to a significant tax reversal, core operational metrics deteriorated substantially, with revenues declining 39.47% year-on-year to ₹739.10 crores and operating margins compressing to multi-quarter lows."
      },
      {
        "title": "Natco Pharma Ltd. Hits Intraday Low Amid Price Pressure on 29 May 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-hits-intraday-low-amid-price-pressure-on-29-may-2026-4020637",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NatcoPharmaLtd_priceRelatedfactors_4020637.png",
        "date": "2026-05-29 14:31:13",
        "description": "Natco Pharma Ltd. experienced a notable decline today, hitting an intraday low of Rs 1085.4, reflecting a sharp price correction amid broader market weakness and sector underperformance. The stock closed with a significant loss, underperforming both its sector and the benchmark Sensex."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/natco-pharma-ltd-is-rated-hold-by-marketsmojo-4018075",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NatcoPharmaLtd_mojoScore_4018075.png",
        "date": "2026-05-28 10:10:04",
        "description": "Natco Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      }
    ],
    "total": 5652,
    "sid": "156274",
    "stock_news_url": "https://www.marketsmojo.com/news/natco-pharma-156274"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "04-Jun-2026",
      "details": "Earning call Transcript for the concall held on May 29 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "03-Jun-2026",
      "details": "NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "30-May-2026",
      "details": "Newspaper Publication of Annual Audited Financial Results for the Quarter and Year ended March 31 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has declared <strong>75%</strong> dividend, ex-date: 18 Feb 26",
          "dt": "2026-02-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has announced <strong>2:10</strong> stock split, ex-date: 26 Nov 15",
          "dt": "2015-11-26",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Natco Pharma Ltd. is Rated Hold

2026-06-19 10:11:29

Natco Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Natco Pharma Falls 12.11%: Key Technical Shifts and Market Pressures This Week

2026-06-14 16:02:59

Key Events This Week

1 June: Intraday low hit amid heavy price pressure

1 June: Technical momentum shifts observed amid volatile conditions

5 June: Week closes at Rs.893.65, down 12.11%

Week Open

Rs.1,016.75

Week Close

Rs.893.65

-12.11%

Read full news article

Natco Pharma Ltd. is Rated Hold by MarketsMOJO

2026-06-08 10:10:40

Natco Pharma Ltd. is currently rated 'Hold' by MarketsMOJO, with this rating last updated on 10 March 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Natco Pharma Ltd. Hits Intraday Low Amid Price Pressure on 1 June 2026

2026-06-01 10:16:51

Natco Pharma Ltd. experienced significant intraday weakness on 1 Jun 2026, with its share price touching a low of Rs 942.45, down 7.31% from the previous close. The stock underperformed its sector and the broader market, reflecting immediate selling pressure amid a cautious market environment.

Read full news article

Natco Pharma Ltd. Technical Momentum Shifts Amid Volatile Market Conditions

2026-06-01 08:00:24

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals. Despite a sharp day decline of 13.51%, the stock’s year-to-date and longer-term returns continue to outperform the Sensex, signalling underlying resilience amid recent volatility.

Read full news article

Are Natco Pharma Ltd. latest results good or bad?

2026-05-30 19:44:38

Natco Pharma Ltd.'s latest financial results for Q4 FY26 reveal a complex picture of operational performance. The company reported a net profit of ₹267.90 crores, which reflects a significant quarter-on-quarter growth of 76.83%. However, this figure is accompanied by a year-on-year decline of 34.11%, indicating challenges in sustaining profitability over a longer period. Net sales for the quarter reached ₹739.10 crores, marking a 14.18% increase from the previous quarter, yet this is overshadowed by a substantial year-on-year decrease of 39.47%. This suggests that while there may be some recovery from the previous quarter, the overall trend remains concerning, particularly given the sharp decline in sales compared to the same quarter last year. The operating margin, excluding other income, fell to 17.26%, which is noted as a multi-quarter low. This decline in operating margin indicates significant pressu...

Read full news article

Natco Pharma Q4 FY26: Sharp Revenue Decline Overshadows Tax Reversal Gains

2026-05-30 12:16:10

Natco Pharma Ltd. reported consolidated net profit of ₹267.90 crores for the quarter ended March 2026, marking a sharp 76.83% quarter-on-quarter surge but a concerning 34.11% year-on-year decline. The Hyderabad-based pharmaceutical manufacturer, with a market capitalisation of ₹21,264 crores, witnessed its stock plummet 13.51% following the results announcement, closing at ₹1,016.75 on May 29, 2026. The quarter's performance reveals a troubling divergence: whilst net profit appeared robust due to a significant tax reversal, core operational metrics deteriorated substantially, with revenues declining 39.47% year-on-year to ₹739.10 crores and operating margins compressing to multi-quarter lows.

Read full news article

Natco Pharma Ltd. Hits Intraday Low Amid Price Pressure on 29 May 2026

2026-05-29 14:31:13

Natco Pharma Ltd. experienced a notable decline today, hitting an intraday low of Rs 1085.4, reflecting a sharp price correction amid broader market weakness and sector underperformance. The stock closed with a significant loss, underperforming both its sector and the benchmark Sensex.

Read full news article

Natco Pharma Ltd. is Rated Hold by MarketsMOJO

2026-05-28 10:10:04

Natco Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

View All News